Abstract:In the current study, a new series of benzenesulfonamides 6a-r was designed and synthesized as dual VEGFR-2 and FGFR1 kinase inhibitors with anti-cancer activity. The 4-trifluoromethyl benzenesulfonamide 6l exhibited the highest dual VEGFR-2/FGFR1 inhibitory activity with IC50 values of 0.025 and 0.026 µM, respectively. It showed a higher activity than sorafenib and staurosporine by 1.8- and 1.3-fold, respectively. Furthermore, compound 6l was further tested on EGFR and PDGFR-β kinases showing IC50 values of 0.106 and 0.077 µM, respectively. The target compounds were tested for their anticancer activity against NCI-60 panel of cancer cell lines at 10 µM concentration, where compound 6l displayed the highest mean growth inhibition percent % (GI%) of 60.38%. Compounds 6a, 6b, 6e, 6f, 6h-l, and 6n-r revealed promising GI% on breast cancer cell lines (MCF-7, T-47D, and MDA-MB-231), and were subjected to IC50 determination on these cell lines. The tested compounds showed a higher activity on T-47D and MCF-7 cell lines over MDA-MB-231 cell line compared to the used reference standard; sorafenib. Compounds 6e, 6h-j, 6l and 6o revealed IC50 values ≤ 20 µM against T-47D cell line, furthermore, they were found to be non-cytotoxic on Vero normal cell line. Furthermore, the effect of the most active compounds 6i, and 6l in T-47D cells on cell cycle analysis progression, cell apoptosis, and apoptosis markers was investigated. Both compounds arrested cell cycle progression at G1 phase, furthermore, they enhanced early and late apoptosis, as well as necrosis. The capability of compounds 6i, and 6l to induce apoptosis was further confirmed by their ability to raise BAX/BCl-2 ratio and caspase-3 level in the treated cells. Cell migration assay revealed that both compounds 6i and 6l have anti-migratory effects compared to control T-47D cells after 24, and 48 h. Molecular docking studies for compounds 6a-r on VEGFR-2 and FGFR1 binding sites showed that they exhibit an analogous binding mode in both target kinases which agrees with that of type II kinase inhibitors.

Design, Synthesis and Evaluation of 6-Aryl-indenoisoquinolone Derivatives Dual Targeting ERα and VEGFR-2 As Anti-Breast Cancer Agents.

Synthesis and Biological Evaluation of 2,3-Diaryl Isoquinolinone Derivatives As Anti-Breast Cancer Agents Targeting ERα and VEGFR-2.

Synthesis and Biological Evaluation of 3-Aryl-quinolin Derivatives As Anti-Breast Cancer Agents Targeting ERα and VEGFR-2.

Design, Synthesis and Biological Evaluation of Novel Indone Derivatives As Selective ERβ Modulators

Structure-activity Relationships of 2, 4-Disubstituted Pyrimidines As Dual ERα/VEGFR-2 Ligands with Anti-Breast Cancer Activity.

Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents

Novel SERMs Based on 3-Aryl-4-aryloxy-2h-chromen-2-one Skeleton - A Possible Way to Dual ERα/VEGFR-2 Ligands for Treatment of Breast Cancer.

Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents.

Design, Synthesis and Biological Evaluation of Novel Dual-Acting Modulators Targeting Both Estrogen Receptor Α (erα) and Lysine-Specific Demethylase 1 (LSD1) for Treatment of Breast Cancer.

Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers

Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesis

Design, Synthesis and in Vitro Evaluation of 6-Amide-2-aryl Benzoxazole/benzimidazole Derivatives Against Tumor Cells by Inhibiting VEGFR-2 Kinase.

Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer

Design, Synthesis and Biological Evaluation of Novel 2-Methoxyestradiol Analogs As Dual Selective Estrogen Receptor Modulators (serms) and Antiangiogenic Agents

Design, synthesis, and biological evaluation of novel quinoline-based EGFR/HER-2 dual-target inhibitors as potential anti-tumor agents

Design, Synthesis, Biological Evaluation of Benzoyl Amide Derivatives Containing Nitrogen Heterocyclic Ring As Potential VEGFR-2 Inhibitors

Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies

Structure-guided Identification of Novel Dual-Targeting Estrogen Receptor Α Degraders with Aromatase Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer

Synthesis and Bio-evaluation of 2-Alkyl Substituted Fluorinated Genistein Analogues Against Breast Cancer.

Design, synthesis, docking, ADMET and anticancer evaluations of N-alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors

Dual Functional Small Molecule Fluorescent Probes for Image-Guided Estrogen Receptor-Specific Targeting Coupled Potent Antiproliferative Potency for Breast Cancer Therapy.